Selexis and KBI Biopharma Enter into Agreements with Immatics for Integrated Approach to Advance Immatics TCR Bispecific Program Towards IND
Read More
JSR Life Sciences operates as the strategic leader of JSR’s biotech and life sciences focused businesses, as well as its affiliate companies including MBL, KBI Biopharma, Selexis, Crown Bioscience and others throughout Europe and the Asia-Pacific region. JSR Life Sciences is committed to the advancement of human health worldwide as a strategic partner to companies that discover, develop and deliver products to treat disease and improve the quality of life for patients. With more than 50 years of experience in materials sciences, JSR is a strategic advanced materials supplier of high technology particles and materials to leading companies specializing in biologics manufacturing, in vitro diagnostics and research products and services.
For more than 20 years, Selexis has been at the forefront of helping the biopharmaceutical industry advance life-saving mAb therapeutics into the clinic and to the market.
At Selexis, we believe in the promise of newer biologics and have committed significant resources to ensure our SUREtechnology Platform™ can meet the new expression challenges that these difficult-to-express proteins present.
We are proud of the role that Selexis’ cell line technology is playing in helping to deliver on the promise of bispecifics, which is a rapidly expanding class of drugs showing impressive results in multiple clinical trials.
Copyright© 2021 Selexis SA. All Rights Reserved.